泊马度胺二零二五年价格与二毫克规格购药指南

Valganciclovir has good efficacy, but it cannot be used in combination with other cytotoxic drugs, as this increases the risk of bone marrow suppression, gastrointestinal and skin adverse reactions.

Selinexor (ATG-010) was approved for marketing by the U.S. Food and Drug Administration (FDA) in 2019. Selinexor blocks the nuclear export of tumor suppressor, growth regulator, and anti-inflammatory proteins by binding to the nuclear export protein XPO1 (CRM1), promoting the accumulation of these proteins in the cell nucleus and enhancing their anti-cancer activity in cells.

Baricitinib is a selective, reversible JAK1 and JAK2 inhibitor that is taken orally once daily. It is currently being developed in clinical trials for the treatment of a variety of inflammatory and autoimmune diseases, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis, atopic dermatitis, systemic lupus erythematosus, ulcerative colitis (UC), and alopecia areata.

Pomalidomide is a third-generation immunomodulatory agent with multiple anti-myeloma mechanisms. It activates the activity of the E3 ubiquitin ligase complex by binding to Cerebrolysin, promotes the ubiquitination and proteolysis of substrate proteins Ikaros and Aiolos, inhibits MM cell proliferation, and exerts immunomodulatory and anti-angiogenic effects. It has significant efficacy in patients with multiple myeloma who are resistant to targeted drugs such as bortezomib and lenalidomide.

Baricitinib is a selective, reversible JAK1 and JAK2 inhibitor that is taken orally once daily. It is currently being developed in clinical trials for the treatment of a variety of inflammatory and autoimmune diseases, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis, atopic dermatitis, systemic lupus erythematosus, ulcerative colitis (UC), and alopecia areata.

Pomalidomide 3 ， ， Cereblon E3 ， Ikaros Aiolos ， MM ， ，